Manchester Intermittent and Daily Diet Type 1 Diabetes App Study (MIDDAS-Type 1)

To assess the safety, acceptability and feasibility of testing Intermittent Low Energy Diet (ILED) and Continuous Low Energy Diet (CLED) programmes for 12 weeks in a real life setting with people with T1D and obesity.

The study described herein is a small randomised, open-label, single centre feasibility study of 12 patients with T1D and obesity. The aim of the study is to assess the safety, acceptability and feasibility of ILED (850kcal/day 2 days/week) and CLED (850kcal/day) over 12 weeks in a real life setting with people with T1D and obesity to help them lose weight and improve their glycaemic control. The low energy diets will involve Nestle Optifast® meal replacements as a total diet replacement (TDR).

People with T1D are becoming increasingly accustomed to remote monitoring of their blood glucose by health professionals using several continuous glucose monitoring devices including the Freestyle Libre® flash glucose monitoring system. The Freestyle Libre® allows healthcare professionals to view patient blood glucose trends and patterns from the web-based platform Libreview®. The study described herein will also assess the safety and practicality of providing remote follow-up support by healthcare professionals (dietitian, nurse and psychologist) to patients with T1D and obesity during the course of implementing the low energy diets. High-frequency remote follow up has been shown to be superior to low-frequency face-to-face care in weight management interventions. Remote care reduces participants' burden to attend face-to-face appointments and may be cost-effective compared with face-to-face care whilst improving access to care. The study described herein will incorporate high-frequency remote follow up via telephone and/or the Oviva® smartphone application facilitating messaging, video calls and self-monitoring of weight and blood pressure. The Freestyle Libre® flash glucose monitoring system will facilitate remote review of blood glucose readings.

Positive results from this feasibility study of two different low energy diets will inform whether one or both diets go forward into a large and longer term randomised efficacy trial following the Medical Research Council complex intervention guidance. This could provide the evidence base to inform the use of low energy diets in individuals with T1D and obesity for weight loss to improve their metabolic status and reduce the risk of cardiovascular and other physical and mental co morbidities associated with T1D.

Eligibility Criteria:
Inclusion Criteria:

* T1D for 12 months or longer
* HbA1c 53-108 mmol/mol
* BMI ≥ 30 kg/m2 and \<50kg/ m2 or ≥27.5 kg/ m2 and \<50kg/ m2 in high-risk minority ethnic groups i.e. South Asian, Black African and African Caribbean
* Multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
* Completed Dose Adjustment For Normal Eating (DAFNE) education
* Access to a Freestyle Libre handset and sensors to monitor blood glucose
* Willing to use the Freestyle Libre® flash glucose monitoring system to monitor blood glucose (flash and capillary) and blood ketones and to record carbohydrate and insulin.
* Access to and ability to use a telephone. If no access to a smartphone running iOS or Android (to view the LibreLink app®) then access to a computer (to upload results to the LibreView website).
* Willing to undertake Optifast® LEDs and have previously sampled Optifast®.
* Negative urine pregnancy test at screening and agreement to maintain contraception or abstinence for the trial (where appropriate)
* Ability to read, understand and communicate in English.

Exclusion Criteria:

* Evidence of severe hypoglycaemia in the last 12 months (more than one episode requiring third party assistance) or hypoglycaemia unawareness.
* Patients with non-stable retinopathy, or grade R2 or later, or had no retinopathy screen within 12 months.
* Patients who lack capacity or are unable to read or understand written or verbal instructions in English or those diagnosed with learning difficulties.
* Confirmed pregnant via a pregnancy test at screening, planning pregnancy in the next 3 months, or currently breast feeding.
* Participants who are currently on treatment with Orlistat or other pharmacological treatments for weight loss e.g. Glucagon-like-peptide-1 (GLP-1).
* Participants who are currently taking a Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor.
* Diagnosed Gastroparesis.
* Participants who have previously had bariatric surgery for weight loss including gastric bypass and sleeve gastrectomy.
* Patients who are on chronic use of steroids (more than 20mg daily of prednisolone or its equivalent).
* Patients with known hypersensitivity to any of the ingredients of Optifast® e.g. fish, milk, soy.
* Taking prohibited medications (see Appendix 3) including warfarin or novel anticoagulants (NOAC), low molecular weight heparin (LMWH) or equivalent anti-coagulants and anti-psychotic medication or other psychotropic medications that may cause excessive weight gain.
* Substance abuse or harmful alcohol use as indicated by a score of 16 or above on the Alcohol Use Disorders Identification Test (AUDIT).\[36\]
* Participants with a diagnosed eating disorder, or patients with severe binge eating assessed by a score of 27 or more on the Binge Eating Scale (BES).\[37\]
* Participants with severe depression assessed by a score of 15 or more on the Patient Health Questionnaire-9 (PHQ-9) questionnaire.\[29\]
* Participants with severe anxiety assessed by a score of 15 or more on the General Anxiety Disorder (GAD-7) questionnaire.\[28\]
* Participants with very low self-efficacy assessed by a score of 35 or less on the Weight Efficacy Lifestyle Questionnaire (WEL-SF).\[30\]
* Participants with severe loss of renal function (eGFR \< 30mL/min/1.73m2).
* Participants with psychiatric or physical comorbidity or scheduled for major surgery, which in the opinion of the treating medical physician, Chief Investigator (CI) or Multidisciplinary Team (MDT) would compromise their safety or adherence to the study.
* Unsatisfactory use of the Freestyle Libre® flash glucose monitoring system or unsafe use of DAFNE/insulin adjustment principles during the 14-day "run-in" period that in the opinion of the medical team may undermine the participant's safety on the trial. This includes flash and capillary monitoring of blood glucose and ketone testing.
* Patients who are currently participating in a diabetes drug trial.